bioRxiv Science⌕ Search

Biology subjects

Delgado, M.

Publications and source records attributed to Delgado, M..

20 records · Page 2Linked to original sources

A neural signature of reward

Using a neurometric approach, we identify and validate a neural signature of reward encoded in a distributed pattern of brain activity using data collected from 21 different studies (N = 2,691). Our model can discriminate between receiving rewards from punishments in completely independent data with 99% accuracy and includes weights located in regions containing a high density of D2/D3 receptors. The model exhibits strong generalizability across a range of tasks probing reward, and a high degree of specificity for reward compared to non-reward constructs. We demonstrate several applications of how this model can infer psychological states of positive affect in the absence of self report. The model is sensitive to changes in brain activity following causal manipulations of homeostatic states, can uncover individual preferences for loss-aversion, and can be used to identify positive affective experiences when watching a television show. Our results suggest that there is a shared neural signature of reward elicited across these different task contexts.

neuroscience↗

Structure-based design of a Cortistatin analog with improved immunoregulatory activity against inflammatory bowel disease (IBD)

Ulcerative colitis and Crohns disease are inflammatory bowel diseases (IBD) that lead to chronic inflammations of the gastrointestinal tract due to an abnormal response of the immune system. Finding new effective drugs to tackle IBD represents a major therapeutic concern since IBD incidence and prevalence is increasing worldwide. Recent studies positioned Cortistatin (CST) as a candidate for IBD treatment due to its anti-inflammatory and immunomodulatory activity. Here, we studied the structural properties of CST using NMR and synthesized and characterized new analogs displaying enriched populations of some native conformations. One of them, Analog 5, preserved the activity against IBD with an increased half-life in serum, overcoming the native hormone limitation and opening the door for the use of CST analogs as therapeutic agents. This work represents a new approach to the rational design of molecules to treat IBD and a possibility for patients that fail to respond to other therapies. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=105 SRC="FIGDIR/small/839787v1_ufig1.gif" ALT="Figure 1"> View larger version (22K): org.highwire.dtl.DTLVardef@b84405org.highwire.dtl.DTLVardef@179d0bdorg.highwire.dtl.DTLVardef@775736org.highwire.dtl.DTLVardef@fea7cd_HPS_FORMAT_FIGEXP M_FIG C_FIG

molecular biology↗